BioCentury | Jan 12, 2021
Product Development

Mesoblast to seek advancement of heart failure cell therapy on 60% composite CV outcomes reduction

...heart failure. Behind Revascor are AZD4831, an MPO...
...steroid-refractory graft-versus-host disease and ARDS.TARGETSMPOMyeloperoxidase (MPO)NLR...
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...expected from AstraZeneca’s oral AZD4831 before year-end. AZD4831 inhibits MPO...
...a variety of other inflammatory conditions. Plasma MPO...
BioCentury | Feb 26, 2020
Distillery Therapeutics

Boosting FGF21 signaling to treat pancreatitis

...lowered disease severity scores and reduced signs of disease including levels of amylase and pancreatic myeloperoxidase...
BioCentury | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

...Description Target Mechanism Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) Verdiperstat (BHV3241) Small molecule myeloperoxidase (MPO) inhibitor MPO...
...verdiperstat (BHV3241) is a myeloperoxidase (MPO) inhibitor, which the biotech hypothesizes will alleviate immune-mediated oxidative stress. MPO...
...Glial cell-derived neurotrophic factor mGluR5 - Metabolic glutamate receptor subtype 5 (mGluR5; GRM5) MPO - Myeloperoxidase...
BioCentury | Sep 27, 2019
Product Development

Lessons from Healey ALS on how to build platform trials quickly

...Description Target Mechanism Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) Verdiperstat (BHV3241) Small molecule myeloperoxidase (MPO) inhibitor MPO...
BioCentury | Jan 25, 2019
Politics, Policy & Law

101 problems with patent eligibility

...The Cleveland Clinic v. True Health Diagnostics LLC , three patents claiming methods for testing myeloperoxidase...
BioCentury | Nov 6, 2018
Distillery Therapeutics

Infectious disease

...In a mouse model of CDI, the compound decreased colonic levels of the inflammation marker myeloperoxidase (MPO)...
BioCentury | Sep 7, 2018
Company News

Biohaven gets rights to AZ's myeloperoxidase inhibitor

...conduct a Phase III trial of BHV3241 to treat multiple system atrophy (MSA). The oral myeloperoxidase (MPO)...
...and Parkinson's disease (PD), according to ClinicalTrials.gov. Under the deal, AZ will not develop additional MPO...
...Pharmaceutical Holding Co. Ltd. (NYSE:BHVN), New Haven, Conn. Business: Neurology Chris Lieu AstraZeneca plc Biohaven Pharmaceutical Holding Co. Ltd. Myeloperoxidase (MPO) Parkinson's...
BioCentury | May 9, 2018
Distillery Therapeutics

Gastrointestinal

...of PIEZO1 or the PIEZO1 inhibitor AT-300 decreased histological disease scores and levels of proinflammatory myeloperoxidase (MPO)...
...2018 doi:10.1038/s41467-018-04194-9 CONTACT: Rodger A. Liddle, Duke University, Durham, N.C. email: rodger.liddle@duke.edu Hongjiang Li AT-300, gsmtx4, gsmtx-4 Duke University Myeloperoxidase (MPO) Piezo-type...
BioCentury | Mar 28, 2018
Distillery Techniques

Biomarkers

...TECHNOLOGY: SNPs A SNP on MPO could help predict the risk of colorectal cancer and predict...
...and 1,175 unaffected individuals from the Chinese population identified an association between a SNP on MPO...
...include validating the SNP in a larger cohort of colorectal cancer patients. DESCRIPTION: SNP on myeloperoxidase (MPO)...
Items per page:
1 - 10 of 51